Management of Periodontal Disease and Alveolar Bone Loss

Periodontal disease encompasses a spectrum of inflammatory conditions affecting the supporting structures of the teeth, culminating in the progressive loss of alveolar bone and, ultimately, tooth loss if left unchecked. Traditional management centres on mechanical debridement, including scaling and root planing, to remove subgingival biofilm and calculus. Adjunctive measures such as local or systemic antimicrobials are employed to suppress pathogenic bacteria. In patients with moderate to advanced disease, surgical interventions may be indicated to achieve complete access for debridement, to reduce pocket depth and to restore soft-tissue architecture. Host modulation therapies that target excessive inflammatory responses and oxidative stress have emerged as a valuable complement to mechanical therapy, seeking to preserve residual bone and promote regeneration. Regenerative approaches, including guided tissue regeneration and the use of growth factors, aim to reconstruct periodontal attachment and restore lost bone. Recent advances in biomaterials, drug delivery systems and molecular targets offer promise for more precise and durable outcomes. Given its high global prevalence and links to systemic health, management strategies must be cost-effective, culturally sensitive and tailored to individual risk profiles to ensure long-term stability and oral health equity.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Management of Periodontal Disease and Alveolar Bone Loss publication trend

The graph below shows the total number of articles in management of periodontal disease and alveolar bone loss across all publications each year (not limited to Nature Index journals).

Technical terms

Periodontal disease: A chronic inflammatory condition affecting the gingiva, periodontal ligament and alveolar bone, driven by bacterial biofilm and host immune responses.

Alveolar bone loss: The progressive resorption of the jawbone surrounding teeth, a hallmark of advanced periodontal disease that leads to tooth mobility.

Osteoclastogenesis: The differentiation and activation of osteoclasts, the bone-resorbing cells, which is upregulated in periodontitis.

Host modulation therapy: Pharmacological intervention aimed at regulating the patient’s immune-inflammatory response rather than targeting pathogens directly.

Matrix metalloproteinases (MMPs): A family of proteolytic enzymes that degrade extracellular matrix components and contribute to connective tissue destruction in periodontitis.

RANKL/OPG pathway: The molecular signalling axis between receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) that governs osteoclast differentiation and bone remodelling.

References

1. Global Prevalence of Periodontal Disease and Lack of Its Surveillance. The Scientific World JOURNAL (2020).
2. Sinensetin protects against periodontitis through binding to Bach1 enhancing its ubiquitination degradation and improving oxidative stress. International Journal of Oral Science (2024).
3. Quercetin Preserves Oral Cavity Health by Mitigating Inflammation and Microbial Dysbiosis. Frontiers in Immunology (2021).
4. Gliclazide reduced oxidative stress, inflammation, and bone loss in an experimental periodontal disease model. Journal of Applied Oral Science (2019).